Pablo Gajate

11PUBLICATIONS
78CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 10, 2026
Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.

Lucía Trilla-Fuertes, Jorge Pedregosa-Barbas, Eugenia García-Fernández

|Apr 29, 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández

|Jun 10, 2023
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.

Nataliya Mar, Yousef Zakharia, Alejandro Falcon

|Feb 11, 2023
Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer.

Jorge Esteban-Villarrubia, Javier Torres-Jiménez, Carolina Bueno-Bravo

|Oct 27, 2022
Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates.

Víctor Albarrán, Diana Isabel Rosero, Jesús Chamorro

|Apr 11, 2022
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.

Jaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux

Pageof 2

Frequent Collaborators

2 joint publications

Víctor Albarrán

1 joint publications

Iván Márquez-Rodas

1 joint publications

Federico Longo

1 joint publications

Maria E Rodriguez-Ruiz